Probucol Combined With Valsartan in Reducing Proteinuria in Diabetes Nephropathy

• Status: Unknown status
• Trial end date: 2017-05-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a prospective randomized controlled, open-labeled study to identify the efficacy of probucol in combination with valsartan in patients with Diabetes nephropathy. The reduction of urinary albumin or proteinuria will be the primary outcome studied. The expected study duration will be 48 weeks.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Guangdong General Hospital; Guangdong Provincial People's Hospital
• Treatments: Probucol; Valsartan

Criteria

Inclusion Criteria:

• Type 2 Diabetes nephropathy

• Urinary albumin excretion 1-3g/24hours

• Serum creatinine < 3mg/dl

Exclusion Criteria:

• Type 1 diabetes mellitus

• Renal diseases other than type 2 Diabetes nephropathy

• Renal artery stenosis

• Severe heart diseases

• Tuberculosis